Quantum News
Sign InSign Up
Back to News
research

AtriCure, Inc. (ATRC) Q4 2025 Earnings Call Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
AtriCure reported Q4 2025 earnings on February 17, 2026, highlighting record revenue growth driven by its atrial fibrillation (Afib) treatment portfolio and surgical ablation tools. CEO Michael Carrel emphasized strong adoption of the company’s hybrid ablation therapies, citing expanded FDA clearances and physician training programs as key growth drivers. CFO Angela Wirick projected 2026 revenue guidance above analyst expectations, attributing optimism to international market expansion and pipeline innovations like the next-gen cryoablation system. Analysts questioned reimbursement challenges and clinical trial timelines, with management reaffirming confidence in payer negotiations and upcoming data readouts for pending devices. Forward-looking statements carried standard SEC disclaimers, noting risks from regulatory hurdles, competition, and trial outcomes, though leadership stressed operational momentum.
AI Audio Summary
0:00 / 0:00
Click to play
generated-image (60).png
Quantum News · Media Library

Understand this faster with AI

ChatGPTAsk ChatGPTPerplexityResearch with PerplexityClaudeExplain with ClaudeGrokDiscuss on Grok

SA Transcripts158.45K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call AtriCure, Inc. (ATRC) Q4 2025 Earnings Call February 17, 2026 4:30 PM EST Company Participants Michael H. Carrel - CEO, President & DirectorAngela Wirick - Chief Financial Officer Conference Call Participants Marissa Bych - Gilmartin Group LLCWilliam Plovanic - Canaccord Genuity Corp., Research DivisionAnna Runci - Piper Sandler & Co., Research DivisionMichael Matson - Needham & Company, LLC, Research DivisionMarie Thibault - BTIG, LLC, Research DivisionLilia-Celine Lozada - JPMorgan Chase & Co, Research DivisionDaniel Stauder - Citizens JMP Securities, LLC, Research DivisionJohn McAulay - Stifel, Nicolaus & Company, Incorporated, Research DivisionJayna Renee Francis - UBS Investment Bank, Research DivisionSuraj Kalia - Oppenheimer & Co. Inc., Research Division Presentation Operator Good afternoon, and welcome to AtriCure's Fourth Quarter and Full Year 2025 Earnings Conference Call. This call is being recorded for replay purposes. [Operator Instructions] I would now like to turn the call over to Marissa Bych from the Gilmartin Group for a few introductory comments. Marissa BychGilmartin Group LLC Great. Thank you. By now, you should have received a copy of the earnings press release. If you have not received a copy, please call (513) 644-4484 to have one e-mailed to you. Before we begin today, let me remind you that the company's remarks include forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties many of which are beyond AtriCure's control, including risks and uncertainties described from time to time in AtriCure's SEC filings. These statements include, but are not limited to, financial expectations and guidance, expectations regarding the potential market opportunity for AtriCure's franchises and growth initiatives, future product approvals and clearances, competition, reimbursement and clinical trial outcomes. AtriCure's results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statements. Additionally, we refer to non-GAAP financial measures specifically constant

Read Original

Tags

quantum-finance

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.